_1777370220974_847775619.png&w=64&q=75){kind=small}
New injection reduces organ fat by 12%
Early human trials of the experimental injection CBL-514 have demonstrated its potential to reduce visceral fat, which surrounds internal organs and increases health risks such as heart failure and diabetes. Participants received injections into their lower abdomen over 12 weeks, resulting in an average 12% decrease in visceral fat, while those on a placebo experienced a 5.68% increase. The drug selectively destroys fat cells without harming nearby tissue, offering potential health benefits beyond cosmetic improvements.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)